Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2015, Article ID 418767, 11 pages
http://dx.doi.org/10.1155/2015/418767
Research Article

In Silico Design of Human IMPDH Inhibitors Using Pharmacophore Mapping and Molecular Docking Approaches

1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China
2Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 10050, China

Received 20 November 2014; Revised 8 January 2015; Accepted 20 January 2015

Academic Editor: John Mitchell

Copyright © 2015 Rui-Juan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. D. Sintchak, M. A. Fleming, O. Futer et al., “Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid,” Cell, vol. 85, no. 6, pp. 921–930, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Hedstrom, “IMP dehydrogenase: structure, mechanism, and inhibition,” Chemical Reviews, vol. 109, no. 7, pp. 2903–2928, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Huberman, D. Glesne, and F. Collart, “Regulation and role of inosine-5′-monophosphate dehydrogenase in cell replication, malignant transformation, and differentiation,” Advances in Experimental Medicine and Biology, vol. 370, pp. 741–746, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Nagai, Y. Natsumeda, Y. Konno, R. Hoffman, S. Irino, and G. Weber, “Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias,” Cancer Research, vol. 51, no. 15, pp. 3886–3890, 1991. View at Google Scholar · View at Scopus
  5. A. Zimmermann, J. J. Gu, J. Spychala, and B. S. Mitchell, “Inosine monophosphate dehydrogenase expression: transcriptional regulation of the type I and type II genes,” Advances in Enzyme Regulation, vol. 36, pp. 75–84, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. A. G. Zimmermann, K. L. Wright, J. P.-Y. Ting, and B. S. Mitchell, “Regulation of inosine-5′-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5′ palindromic octamer sequence,” Journal of Biological Chemistry, vol. 272, no. 36, pp. 22913–22923, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Zimmermann, J. J. Gu, J. Laliberté, and B. S. Mitchell, “Inosine-5′-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation,” Progress in nucleic acid research and molecular biology, vol. 61, pp. 181–209, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Jain, S. J. Almquist, P. J. Ford et al., “Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes,” Biochemical Pharmacology, vol. 67, no. 4, pp. 767–776, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Wang, A. Zeevi, S. Webber et al., “A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity,” Pharmacogenetics and Genomics, vol. 17, no. 4, pp. 283–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-E. F. Mohamed, R. F. Frye, and T. Y. Langaee, “Interpopulation variation frequency of human inosine 5′-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms,” Genetic Testing, vol. 12, no. 4, pp. 513–516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. T.-Y. Wu, Y. Peng, L. L. Pelleymounter et al., “Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics,” British Journal of Pharmacology, vol. 161, no. 7, pp. 1584–1598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Felczak and K. W. Pankiewicz, “Rehab of NAD(P)-dependent enzymes with NAD(P)-based inhibitors,” Current Medicinal Chemistry, vol. 18, no. 13, pp. 1891–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Chen, R. Petrelli, K. Felczak et al., “Nicotinamide adenine dinucleotide based therapeutics,” Current Medicinal Chemistry, vol. 15, no. 7, pp. 650–670, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. B. Braun-Sand and M. Peetz, “Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics,” Future Medicinal Chemistry, vol. 2, no. 1, pp. 81–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Gorla, N. N. McNair, G. Yang et al., “Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 3, pp. 1603–1614, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Hedstrom, G. Liechti, J. B. Goldberg, and D. R. Gollapalli, “The antibiotic potential of prokaryotic IMP dehydrogenase inhibitors,” Current Medicinal Chemistry, vol. 18, no. 13, pp. 1909–1918, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. R. Chong, D. Z. Qian, F. Pan et al., “Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target,” Journal of Medicinal Chemistry, vol. 49, no. 9, pp. 2677–2680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Petrelli, P. Vita, I. Torquati et al., “Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, no. 2, pp. 103–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. M. D. Vu, S. Qi, D. Xu et al., “Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat,” Transplantation, vol. 66, no. 12, pp. 1575–1580, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. A. H. Miladipour, A. J. Ghods, and H. Nejadgashti, “Effect of mycophenolate mofetil on the prevention of acute renal allograft rejection,” Transplantation Proceedings, vol. 34, no. 6, pp. 2089–2090, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. “Phase II clinical trial of VX-497 for HCV infection begins,” AIDS Patient Care STDS, vol. 12, no. 12, p. 944, 1998.
  22. A. Panattoni, F. D'Anna, and E. Triolo, “Antiviral activity of tiazofurin and mycophenolic acid against Grapevine Leafroll-associated Virus 3 in Vitis vinifera explants,” Antiviral Research, vol. 73, no. 3, pp. 206–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Kiguchi, F. R. Collart, C. Henning-Chubb, and E. Huberman, “Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin,” Experimental Cell Research, vol. 187, no. 1, pp. 47–53, 1990. View at Publisher · View at Google Scholar · View at Scopus
  24. T. G. M. Dhar, S. H. Watterson, P. Chen et al., “Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 3, pp. 547–551, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. H. Watterson, M. Carlsen, T. G. M. Dhar et al., “Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 3, pp. 543–546, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. H. Watterson, C. Liu, T. G. M. Dhar et al., “Novel amide-based inhibitors of inosine 5′-monophosphate dehydrogenase,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 20, pp. 2879–2882, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. S. H. Watterson, T. G. M. Dhar, S. K. Ballentine et al., “Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 7, pp. 1273–1276, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. R. E. Beevers, G. M. Buckley, N. Davies et al., “Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 9, pp. 2539–2542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Tai, T. Lu, H. Yuan et al., “Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors,” Journal of Molecular Modeling, vol. 18, no. 7, pp. 3087–3100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y.-L. Wang, C.-Y. Lin, K.-C. Shih, J.-W. Huang, and C.-Y. Tang, “Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 23, pp. 6286–6291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C.-Y. Lin and Y.-L. Wang, “Novel design strategy for checkpoint kinase 2 inhibitors using pharmacophore modeling, combinatorial fusion, and virtual screening,” BioMed Research International, vol. 2014, Article ID 359494, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. Accelrys Inc, “Discovery Studio User manual,” Discovery Studio Version 3.0, 2011.
  33. Schrödinger LLC, “Schrödinger user manuals,” Glide Version 9.3, 2014.
  34. T. G. M. Dhar, Z. Shen, J. Guo et al., “Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4-morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity,” Journal of Medicinal Chemistry, vol. 45, no. 11, pp. 2127–2130, 2002. View at Publisher · View at Google Scholar
  35. D. Floryk and T. C. Thompson, “Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells,” International Journal of Cancer, vol. 123, no. 10, pp. 2294–2302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Jain, S. J. Almquist, D. Shlyakhter, and M. W. Harding, “VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent,” Journal of Pharmaceutical Sciences, vol. 90, no. 5, pp. 625–637, 2001. View at Google Scholar
  37. J. Jain, S. J. Almquist, A. D. Heiser et al., “Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5′-monophosphate dehydrogenase inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 3, pp. 1272–1277, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. H. H. Gu, E. J. Iwanowicz, J. Guo et al., “Novel diamide-based inhibitors of IMPDH,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 9, pp. 1323–1326, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. S. H. Watterson, P. Chen, Y. Zhao et al., “Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419),” Journal of Medicinal Chemistry, vol. 50, no. 15, pp. 3730–3742, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Nakanishi, Y. Kozuki, Y. Eikyu et al., “In vitro and in vivo characterization of AS2643361, a novel and highly potent inosine 5′-monophosphate dehydrogenase inhibitor,” European Journal of Pharmacology, vol. 674, no. 1, pp. 58–63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. G. M. Buckley, N. Davies, H. J. Dyke et al., “Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 3, pp. 751–754, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. T. G. M. Dhar, Z. Shen, C. A. Fleener et al., “The TosMIC approach to 3-(oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 12, no. 22, pp. 3305–3308, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. R. P. Gangwal, N. R. Das, K. Thanki et al., “Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening,” Journal of Molecular Graphics and Modelling, vol. 49, pp. 18–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Kalva, E. R. Azhagiya Singam, V. Rajapandian, L. M. Saleena, and V. Subramanian, “Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies,” Journal of Molecular Graphics and Modelling, vol. 49, pp. 25–37, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Madhavi Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman, “Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments,” Journal of Computer-Aided Molecular Design, vol. 27, no. 3, pp. 221–234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. Friesner, R. B. Murphy, M. P. Repasky et al., “Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6177–6196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. M. D. Sintchak and E. Nimmesgern, “The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors,” Immunopharmacology, vol. 47, no. 2-3, pp. 163–184, 2000. View at Publisher · View at Google Scholar · View at Scopus